CRVS Corvus Pharmaceuticals Inc

Price (delayed)

$2.205

Market cap

$137.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$131.51M

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells ...

Highlights
The debt has plunged by 55% YoY and by 24% from the previous quarter
The EPS has increased by 42% YoY and by 9% QoQ
Corvus Pharmaceuticals's equity has decreased by 32% YoY and by 14% QoQ
The quick ratio has contracted by 22% YoY and by 17% from the previous quarter

Key stats

What are the main financial stats of CRVS
Market
Shares outstanding
62.55M
Market cap
$137.93M
Enterprise value
$131.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$24.86M
EBITDA
-$24.74M
Free cash flow
-$20.98M
Per share
EPS
-$0.51
Free cash flow per share
-$0.43
Book value per share
$0.68
Revenue per share
$0
TBVPS
$0.82
Balance sheet
Total assets
$40.08M
Total liabilities
$6.72M
Debt
$1.04M
Equity
$33.36M
Working capital
$16.13M
Liquidity
Debt to equity
0.03
Current ratio
3.4
Quick ratio
3.3
Net debt/EBITDA
0.26
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-50.8%
Return on equity
-60%
Return on invested capital
-79.5%
Return on capital employed
-74.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
1.61%
1 week
3.04%
1 month
23.88%
1 year
-4.13%
YTD
25.28%
QTD
21.15%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.09M
Net income
-$24.86M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has increased by 39% YoY and by 8% QoQ
The operating income rose by 27% year-on-year

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 42% YoY and by 9% QoQ
The price to book (P/B) is 128% higher than the 5-year quarterly average of 1.4 and 45% higher than the last 4 quarters average of 2.2
Corvus Pharmaceuticals's equity has decreased by 32% YoY and by 14% QoQ

Efficiency

How efficient is Corvus Pharmaceuticals business performance
The ROE is up by 8% year-on-year
The company's return on assets rose by 7% YoY
Corvus Pharmaceuticals's return on invested capital has increased by 7% YoY but it has decreased by 3.5% QoQ

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
The total assets has contracted by 31% YoY and by 12% from the previous quarter
Corvus Pharmaceuticals's total liabilities has decreased by 28% YoY and by 2.2% QoQ
The debt is 97% less than the equity
The debt has plunged by 55% YoY and by 24% from the previous quarter
The debt to equity has declined by 40% year-on-year and by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.